Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients
Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is increasing interest in metabolic and lipoprotein signatures of the disease, and early analyses have demonstrated a metabolic pattern typical for ath...
Saved in:
| Published in: | Frontiers in molecular biosciences Vol. 8; p. 737039 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Switzerland
Frontiers Media S.A
02.12.2021
|
| Subjects: | |
| ISSN: | 2296-889X, 2296-889X |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is increasing interest in metabolic and lipoprotein signatures of the disease, and early analyses have demonstrated a metabolic pattern typical for atherosclerotic and hepatic damage in COVID-19 patients. However, it remains unclear whether this is specific for COVID-19 and whether the observed signature is caused by the disease or rather represents an underlying risk factor. To answer this question, we have analyzed 482 serum samples using nuclear magnetic resonance metabolomics, including longitudinally collected samples from 12 COVID-19 and 20 cardiogenic shock intensive care patients, samples from 18 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody-positive individuals, and single time point samples from 58 healthy controls. COVID-19 patients showed a distinct metabolic serum profile, including changes typical for severe dyslipidemia and a deeply altered metabolic status compared with healthy controls. Specifically, very-low-density lipoprotein and intermediate-density lipoprotein particles and associated apolipoprotein B and intermediate-density lipoprotein cholesterol were significantly increased, whereas cholesterol and apolipoprotein A2 were decreased. Moreover, a similarly perturbed profile was apparent when compared with other patients with cardiogenic shock who are in the intensive care unit when looking at a 1-week time course, highlighting close links between COVID-19 and lipid metabolism. The metabolic profile of COVID-19 patients distinguishes those from healthy controls and also from patients with cardiogenic shock. In contrast, anti-SARS-CoV-2 antibody-positive individuals without acute COVID-19 did not show a significantly perturbed metabolic profile compared with age- and sex-matched healthy controls, but SARS-CoV-2 antibody-titers correlated significantly with metabolic parameters, including levels of glycine, ApoA2, and small-sized low- and high-density lipoprotein subfractions. Our data suggest that COVID-19 is associated with dyslipidemia, which is not observed in anti-SARS-CoV-2 antibody-positive individuals who have not developed severe courses of the disease. This suggests that lipoprotein profiles may represent a confounding risk factor for COVID-19 with potential for patient stratification. |
|---|---|
| AbstractList | Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is increasing interest in metabolic and lipoprotein signatures of the disease, and early analyses have demonstrated a metabolic pattern typical for atherosclerotic and hepatic damage in COVID-19 patients. However, it remains unclear whether this is specific for COVID-19 and whether the observed signature is caused by the disease or rather represents an underlying risk factor. To answer this question, we have analyzed 482 serum samples using nuclear magnetic resonance metabolomics, including longitudinally collected samples from 12 COVID-19 and 20 cardiogenic shock intensive care patients, samples from 18 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody-positive individuals, and single time point samples from 58 healthy controls. COVID-19 patients showed a distinct metabolic serum profile, including changes typical for severe dyslipidemia and a deeply altered metabolic status compared with healthy controls. Specifically, very-low-density lipoprotein and intermediate-density lipoprotein particles and associated apolipoprotein B and intermediate-density lipoprotein cholesterol were significantly increased, whereas cholesterol and apolipoprotein A2 were decreased. Moreover, a similarly perturbed profile was apparent when compared with other patients with cardiogenic shock who are in the intensive care unit when looking at a 1-week time course, highlighting close links between COVID-19 and lipid metabolism. The metabolic profile of COVID-19 patients distinguishes those from healthy controls and also from patients with cardiogenic shock. In contrast, anti-SARS-CoV-2 antibody-positive individuals without acute COVID-19 did not show a significantly perturbed metabolic profile compared with age- and sex-matched healthy controls, but SARS-CoV-2 antibody-titers correlated significantly with metabolic parameters, including levels of glycine, ApoA2, and small-sized low- and high-density lipoprotein subfractions. Our data suggest that COVID-19 is associated with dyslipidemia, which is not observed in anti-SARS-CoV-2 antibody-positive individuals who have not developed severe courses of the disease. This suggests that lipoprotein profiles may represent a confounding risk factor for COVID-19 with potential for patient stratification. Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is increasing interest in metabolic and lipoprotein signatures of the disease, and early analyses have demonstrated a metabolic pattern typical for atherosclerotic and hepatic damage in COVID-19 patients. However, it remains unclear whether this is specific for COVID-19 and whether the observed signature is caused by the disease or rather represents an underlying risk factor. To answer this question, we have analyzed 482 serum samples using nuclear magnetic resonance metabolomics, including longitudinally collected samples from 12 COVID-19 and 20 cardiogenic shock intensive care patients, samples from 18 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody-positive individuals, and single time point samples from 58 healthy controls. COVID-19 patients showed a distinct metabolic serum profile, including changes typical for severe dyslipidemia and a deeply altered metabolic status compared with healthy controls. Specifically, very-low-density lipoprotein and intermediate-density lipoprotein particles and associated apolipoprotein B and intermediate-density lipoprotein cholesterol were significantly increased, whereas cholesterol and apolipoprotein A2 were decreased. Moreover, a similarly perturbed profile was apparent when compared with other patients with cardiogenic shock who are in the intensive care unit when looking at a 1-week time course, highlighting close links between COVID-19 and lipid metabolism. The metabolic profile of COVID-19 patients distinguishes those from healthy controls and also from patients with cardiogenic shock. In contrast, anti-SARS-CoV-2 antibody-positive individuals without acute COVID-19 did not show a significantly perturbed metabolic profile compared with age- and sex-matched healthy controls, but SARS-CoV-2 antibody-titers correlated significantly with metabolic parameters, including levels of glycine, ApoA2, and small-sized low- and high-density lipoprotein subfractions. Our data suggest that COVID-19 is associated with dyslipidemia, which is not observed in anti-SARS-CoV-2 antibody-positive individuals who have not developed severe courses of the disease. This suggests that lipoprotein profiles may represent a confounding risk factor for COVID-19 with potential for patient stratification.Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is increasing interest in metabolic and lipoprotein signatures of the disease, and early analyses have demonstrated a metabolic pattern typical for atherosclerotic and hepatic damage in COVID-19 patients. However, it remains unclear whether this is specific for COVID-19 and whether the observed signature is caused by the disease or rather represents an underlying risk factor. To answer this question, we have analyzed 482 serum samples using nuclear magnetic resonance metabolomics, including longitudinally collected samples from 12 COVID-19 and 20 cardiogenic shock intensive care patients, samples from 18 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody-positive individuals, and single time point samples from 58 healthy controls. COVID-19 patients showed a distinct metabolic serum profile, including changes typical for severe dyslipidemia and a deeply altered metabolic status compared with healthy controls. Specifically, very-low-density lipoprotein and intermediate-density lipoprotein particles and associated apolipoprotein B and intermediate-density lipoprotein cholesterol were significantly increased, whereas cholesterol and apolipoprotein A2 were decreased. Moreover, a similarly perturbed profile was apparent when compared with other patients with cardiogenic shock who are in the intensive care unit when looking at a 1-week time course, highlighting close links between COVID-19 and lipid metabolism. The metabolic profile of COVID-19 patients distinguishes those from healthy controls and also from patients with cardiogenic shock. In contrast, anti-SARS-CoV-2 antibody-positive individuals without acute COVID-19 did not show a significantly perturbed metabolic profile compared with age- and sex-matched healthy controls, but SARS-CoV-2 antibody-titers correlated significantly with metabolic parameters, including levels of glycine, ApoA2, and small-sized low- and high-density lipoprotein subfractions. Our data suggest that COVID-19 is associated with dyslipidemia, which is not observed in anti-SARS-CoV-2 antibody-positive individuals who have not developed severe courses of the disease. This suggests that lipoprotein profiles may represent a confounding risk factor for COVID-19 with potential for patient stratification. |
| Author | Ragab, Mohab Eitel, Ingo Ehlers, Marc Meyer-Saraei, Roza Lixenfeld, Anne Sophie Martin, Emily Graf, Tobias Sina, Christian Lehrian, Selina Künsting, Inga Käding, Nadja von Kopylow, Vera Föh, Bandik Taube, Stefan Kreutzmann, Fabian Mallagaray, Alvaro Rahmöller, Johann Günther, Ulrich L. Schmelter, Franziska Jantzen, Eckard |
| AuthorAffiliation | 2 Research and Development Department, GALAB Laboratories GmbH, Hamburg , Germany 3 Medical Department I, University Hospital Schleswig-Holstein, Lübeck , Germany 9 Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck , Germany 8 Institute of Virology and Cell Biology, University of Lübeck, Lübeck , Germany 1 Institute of Nutritional Medicine, University of Lübeck, Lübeck , Germany 6 Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, Lübeck , Germany 5 Department of Anesthesiology and Intensive Care, University Medical Center Schleswig-Holstein, Lübeck , Germany 7 German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck , Germany 4 Institute of Chemistry and Metabolomics, University of Lübeck, Lübeck , Germany |
| AuthorAffiliation_xml | – name: 1 Institute of Nutritional Medicine, University of Lübeck, Lübeck , Germany – name: 6 Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, Lübeck , Germany – name: 3 Medical Department I, University Hospital Schleswig-Holstein, Lübeck , Germany – name: 5 Department of Anesthesiology and Intensive Care, University Medical Center Schleswig-Holstein, Lübeck , Germany – name: 9 Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck , Germany – name: 4 Institute of Chemistry and Metabolomics, University of Lübeck, Lübeck , Germany – name: 7 German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck , Germany – name: 2 Research and Development Department, GALAB Laboratories GmbH, Hamburg , Germany – name: 8 Institute of Virology and Cell Biology, University of Lübeck, Lübeck , Germany |
| Author_xml | – sequence: 1 givenname: Franziska surname: Schmelter fullname: Schmelter, Franziska – sequence: 2 givenname: Bandik surname: Föh fullname: Föh, Bandik – sequence: 3 givenname: Alvaro surname: Mallagaray fullname: Mallagaray, Alvaro – sequence: 4 givenname: Johann surname: Rahmöller fullname: Rahmöller, Johann – sequence: 5 givenname: Marc surname: Ehlers fullname: Ehlers, Marc – sequence: 6 givenname: Selina surname: Lehrian fullname: Lehrian, Selina – sequence: 7 givenname: Vera surname: von Kopylow fullname: von Kopylow, Vera – sequence: 8 givenname: Inga surname: Künsting fullname: Künsting, Inga – sequence: 9 givenname: Anne Sophie surname: Lixenfeld fullname: Lixenfeld, Anne Sophie – sequence: 10 givenname: Emily surname: Martin fullname: Martin, Emily – sequence: 11 givenname: Mohab surname: Ragab fullname: Ragab, Mohab – sequence: 12 givenname: Roza surname: Meyer-Saraei fullname: Meyer-Saraei, Roza – sequence: 13 givenname: Fabian surname: Kreutzmann fullname: Kreutzmann, Fabian – sequence: 14 givenname: Ingo surname: Eitel fullname: Eitel, Ingo – sequence: 15 givenname: Stefan surname: Taube fullname: Taube, Stefan – sequence: 16 givenname: Nadja surname: Käding fullname: Käding, Nadja – sequence: 17 givenname: Eckard surname: Jantzen fullname: Jantzen, Eckard – sequence: 18 givenname: Tobias surname: Graf fullname: Graf, Tobias – sequence: 19 givenname: Christian surname: Sina fullname: Sina, Christian – sequence: 20 givenname: Ulrich L. surname: Günther fullname: Günther, Ulrich L. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34938772$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kklvEzEAhS1URBf6A7igOXKZ4G28XJBQSmmklHAAxM2yx57WZcZObacS_Po6SYtaJE7e3vuebL9jcBBicAC8QXBGiJDvhymOZoYhRjNOOCTyBTjCWLJWCPnz4Mn8EJzmfAMhRB0knNFX4JBQSQTn-AiES1e0iaPvGx1ss_Rrb-NUV5c6_XIpN2d-GFxyoXhdXDNf_VictUg25ylOzZcY2ouY177o0f9xdodYlWuXmkUoLmR_Vy06uearLr4y8mvwctBjdqcP4wn4fv7p2_yiXa4-L-Yfl21PWVfaDnaEG2k55Z2BZkCUaSg6Sw2EVDJDuUWCC4esQNxKMjBu4CDEIDvaw86RE7DYc23UN2qd_KTTbxW1V7uNmK6UTsX3o1PGVD4ikmBCKSPWQCuFJoxiLTDtWWV92LPWGzM529d7JD0-gz4_Cf5aXcU7JZhgSOAKePcASPF243JRk8-9G0cdXNxkhRkiWBLYySp9-zTrb8jjh1UB3wv6FHNOblB9ff3i4zbajwpBtW2H2rVDbduh9u2oTvSP8xH-f889FQW9hg |
| CitedBy_id | crossref_primary_10_1002_jmv_27929 crossref_primary_10_1038_s41598_023_40999_5 crossref_primary_10_1155_2022_8067857 crossref_primary_10_1002_anie_202306154 crossref_primary_10_1016_j_jhepr_2025_101450 crossref_primary_10_1016_j_ejr_2022_01_004 crossref_primary_10_1038_s41598_024_74641_9 crossref_primary_10_1371_journal_ppat_1010443 crossref_primary_10_3390_ijms242417437 crossref_primary_10_3390_metabo12030230 crossref_primary_10_1093_jamia_ocaf070 crossref_primary_10_1038_s41598_025_91965_2 crossref_primary_10_3390_biom15071027 crossref_primary_10_3390_metabo12121206 crossref_primary_10_1016_j_heliyon_2024_e37115 crossref_primary_10_1055_a_1860_2610 crossref_primary_10_3390_antiox12112009 crossref_primary_10_3390_microbiolres15020029 crossref_primary_10_1002_ange_202306154 crossref_primary_10_1016_j_heliyon_2023_e15010 crossref_primary_10_1007_s43440_023_00517_w crossref_primary_10_1093_ibd_izad298 crossref_primary_10_1016_j_pnmrs_2023_10_002 crossref_primary_10_3390_ijms241411614 crossref_primary_10_1186_s12014_023_09403_2 crossref_primary_10_3389_fimmu_2023_1144224 crossref_primary_10_3390_metabo14040195 crossref_primary_10_1002_iid3_861 crossref_primary_10_3390_metabo12121277 crossref_primary_10_1007_s00109_023_02396_3 crossref_primary_10_3390_nu14112194 crossref_primary_10_1007_s00216_024_05706_x crossref_primary_10_1016_j_bbadis_2025_167806 |
| Cites_doi | 10.1038/s41380-021-01148-4 10.3389/fmed.2020.00370 10.1161/01.cir.0000131511.50734.44 10.1016/S2213-2600(20)30229-0 10.1016/j.cpcardiol.2020.100618 10.1161/01.CIR.90.1.42 10.1017/S000711450769936X 10.1016/j.isci.2020.101645 10.7554/eLife.65962 10.1093/bioinformatics/bti476 10.1001/jama.298.3.299 10.1177/09612033070160040901 10.1093/eurheartj/ehx580 10.1016/S0140-6736(14)61177-6 10.1021/ac5025039 10.1161/JAHA.115.002621 10.1002/bit.260380602 10.1016/S0271-5317(99)00118-9 10.1016/j.cell.2020.05.032 10.1172/jci.insight.140327 10.1101/2021.01.13.21249645 10.1006/jmre.2000.2071 10.1016/S2213-2600(20)30076-X 10.1007/BF00145358 10.3389/fmed.2020.00423 10.1001/jamaneurol.2020.1127 10.1161/JAHA.115.002765 10.1101/2020.02.08.20021212 10.1186/1471-2105-12-366 10.3390/jcm7110378 10.1093/eurheartj/ehz962 10.1093/nsr/nwaa086 10.1021/acs.jproteome.0c00519 10.1016/j.jacc.2018.04.050 10.1038/s41569-020-0413-9 10.1111/liv.14435 10.3390/nu11061356 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 Schmelter, Föh, Mallagaray, Rahmöller, Ehlers, Lehrian, von Kopylow, Künsting, Lixenfeld, Martin, Ragab, Meyer-Saraei, Kreutzmann, Eitel, Taube, Käding, Jantzen, Graf, Sina and Günther. Copyright © 2021 Schmelter, Föh, Mallagaray, Rahmöller, Ehlers, Lehrian, von Kopylow, Künsting, Lixenfeld, Martin, Ragab, Meyer-Saraei, Kreutzmann, Eitel, Taube, Käding, Jantzen, Graf, Sina and Günther. 2021 Schmelter, Föh, Mallagaray, Rahmöller, Ehlers, Lehrian, von Kopylow, Künsting, Lixenfeld, Martin, Ragab, Meyer-Saraei, Kreutzmann, Eitel, Taube, Käding, Jantzen, Graf, Sina and Günther |
| Copyright_xml | – notice: Copyright © 2021 Schmelter, Föh, Mallagaray, Rahmöller, Ehlers, Lehrian, von Kopylow, Künsting, Lixenfeld, Martin, Ragab, Meyer-Saraei, Kreutzmann, Eitel, Taube, Käding, Jantzen, Graf, Sina and Günther. – notice: Copyright © 2021 Schmelter, Föh, Mallagaray, Rahmöller, Ehlers, Lehrian, von Kopylow, Künsting, Lixenfeld, Martin, Ragab, Meyer-Saraei, Kreutzmann, Eitel, Taube, Käding, Jantzen, Graf, Sina and Günther. 2021 Schmelter, Föh, Mallagaray, Rahmöller, Ehlers, Lehrian, von Kopylow, Künsting, Lixenfeld, Martin, Ragab, Meyer-Saraei, Kreutzmann, Eitel, Taube, Käding, Jantzen, Graf, Sina and Günther |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fmolb.2021.737039 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Schmelter et al |
| EISSN | 2296-889X |
| ExternalDocumentID | oai_doaj_org_article_bbbf11393234463db0d98a3642a824c6 PMC8686182 34938772 10_3389_fmolb_2021_737039 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAYXX ACGFS ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION GROUPED_DOAJ HYE KQ8 M48 M~E OK1 PGMZT RPM ACXDI IAO IEA IHR IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c465t-50537b9d7475b0bf146a085d4b00496b47d1878e1d817d93f67b0f88f954c05e3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 33 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000731695600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2296-889X |
| IngestDate | Fri Oct 03 12:29:25 EDT 2025 Thu Aug 21 14:10:45 EDT 2025 Fri Sep 05 07:05:57 EDT 2025 Thu Jan 02 22:55:44 EST 2025 Tue Nov 18 22:13:10 EST 2025 Sat Nov 29 05:32:42 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 NMR SARS-CoV-2 metabolomics lipoproteins |
| Language | English |
| License | Copyright © 2021 Schmelter, Föh, Mallagaray, Rahmöller, Ehlers, Lehrian, von Kopylow, Künsting, Lixenfeld, Martin, Ragab, Meyer-Saraei, Kreutzmann, Eitel, Taube, Käding, Jantzen, Graf, Sina and Günther. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c465t-50537b9d7475b0bf146a085d4b00496b47d1878e1d817d93f67b0f88f954c05e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Sander Kooijman, Leiden University Medical Center, Netherlands Toby James Athersuch, Imperial College London, United Kingdom These authors have contributed equally to this work and share senior authorship These authors have contributed equally to this work and share first authorship This article was submitted to Metabolomics, a section of the journal Frontiers in Molecular Biosciences Edited by: Emmanuel Mikros, National and Kapodistrian University of Athens, Greece |
| OpenAccessLink | https://doaj.org/article/bbbf11393234463db0d98a3642a824c6 |
| PMID | 34938772 |
| PQID | 2613293059 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bbbf11393234463db0d98a3642a824c6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8686182 proquest_miscellaneous_2613293059 pubmed_primary_34938772 crossref_citationtrail_10_3389_fmolb_2021_737039 crossref_primary_10_3389_fmolb_2021_737039 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-02 |
| PublicationDateYYYYMMDD | 2021-12-02 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in molecular biosciences |
| PublicationTitleAlternate | Front Mol Biosci |
| PublicationYear | 2021 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Borén (B4) 2020; 41 Sachet (B28) 2007; 16 Bornstein (B5) 2021 Li (B16) 2020 Xu (B36) 2020; 8 Thomas (B34) 2020; 5 Xu (B37) 2020; 40 Smilde (B33) 2005; 21 Nishiga (B20) 2020; 17 Saeed (B29) 2018; 72 Mao (B18) 2020; 77 Sanders (B30) 2021; 10 Joshi (B13) 2016; 5 Schmelter (B31) 2021 Li (B15) 2007; 98 Alves (B1) 2019; 11 Ding (B8) 2016; 5 Ludwig (B17) 2011; 12 Carmena (B7) 2004; 109 Prasad (B26) 2020; 7 Nordestgaard (B23) 2007; 298 Bruzzone (B6) 2020; 23 Pastori (B25) 2018; 7 Zaim (B38) 2020; 45 Park (B24) 1999; 19 (B2) 2020 Masip (B19) 2018; 39 Nordestgaard (B22) 2014; 384 Wu (B35) 2020; 7 Hodis (B12) 1994; 90 Nordestgaard (B21) 1992; 8 Duval (B10) 1991; 38 Günther (B11) 2000; 145 Kimhofer (B14) 2020; 19 Dona (B9) 2014; 86 Shen (B32) 2020; 182 Benedetti (B3) 2020; 7 Ronco (B27) 2020; 8 |
| References_xml | – start-page: 1 year: 2021 ident: B5 article-title: Chronic post-COVID-19 Syndrome and Chronic Fatigue Syndrome: Is There a Role for Extracorporeal Apheresis? publication-title: Mol. Psychiatry doi: 10.1038/s41380-021-01148-4 – volume: 7 start-page: 370 year: 2020 ident: B26 article-title: Single Virus Targeting Multiple Organs: What We Know and where We Are Heading? publication-title: Front. Med. doi: 10.3389/fmed.2020.00370 – volume: 109 start-page: 109 year: 2004 ident: B7 article-title: Atherogenic Lipoprotein Particles in Atherosclerosis publication-title: Circulation doi: 10.1161/01.cir.0000131511.50734.44 – volume: 8 start-page: 738 year: 2020 ident: B27 article-title: Management of Acute Kidney Injury in Patients with COVID-19 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30229-0 – volume: 45 start-page: 100618 year: 2020 ident: B38 article-title: COVID-19 and Multiorgan Response publication-title: Curr. Probl. Cardiol. doi: 10.1016/j.cpcardiol.2020.100618 – volume: 90 start-page: 42 year: 1994 ident: B12 article-title: Triglyceride- and Cholesterol-Rich Lipoproteins Have a Differential Effect on Mild/moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin publication-title: Circulation doi: 10.1161/01.CIR.90.1.42 – volume: 98 start-page: 237 year: 2007 ident: B15 article-title: Amino Acids and Immune Function publication-title: Br. J. Nutr. doi: 10.1017/S000711450769936X – volume: 23 start-page: 101645 year: 2020 ident: B6 article-title: SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum publication-title: iScience doi: 10.1016/j.isci.2020.101645 – volume: 10 start-page: e65962 year: 2021 ident: B30 article-title: SARS-CoV-2 Requires Cholesterol for Viral Entry and Pathological Syncytia Formation publication-title: eLife doi: 10.7554/eLife.65962 – volume: 21 start-page: 3043 year: 2005 ident: B33 article-title: ANOVA-simultaneous Component Analysis (ASCA): a New Tool for Analyzing Designed Metabolomics Data publication-title: Bioinformatics doi: 10.1093/bioinformatics/bti476 – volume: 298 start-page: 299 year: 2007 ident: B23 article-title: Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women publication-title: Jama doi: 10.1001/jama.298.3.299 – volume: 16 start-page: 273 year: 2007 ident: B28 article-title: Chloroquine Increases Low-Density Lipoprotein Removal from Plasma in Systemic Lupus Patients publication-title: Lupus doi: 10.1177/09612033070160040901 – volume: 39 start-page: 17 year: 2018 ident: B19 article-title: Indications and Practical Approach to Non-invasive Ventilation in Acute Heart Failure publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehx580 – volume: 384 start-page: 626 year: 2014 ident: B22 article-title: Triglycerides and Cardiovascular Disease publication-title: The Lancet doi: 10.1016/S0140-6736(14)61177-6 – volume: 86 start-page: 9887 year: 2014 ident: B9 article-title: Precision High-Throughput Proton NMR Spectroscopy of Human Urine, Serum, and Plasma for Large-Scale Metabolic Phenotyping publication-title: Anal. Chem. doi: 10.1021/ac5025039 – volume: 5 start-page: e002621 year: 2016 ident: B8 article-title: Plasma glycine and Risk of Acute Myocardial Infarction in Patients with Suspected Stable Angina Pectoris publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.115.002621 – volume: 38 start-page: 561 year: 1991 ident: B10 article-title: Factors Controlling Cell Proliferation and Antibody Production in Mouse Hybridoma Cells: I. Influence of the Amino Acid Supply publication-title: Biotechnol. Bioeng. doi: 10.1002/bit.260380602 – volume: 19 start-page: 1777 year: 1999 ident: B24 article-title: Dietary Taurine or glycine Supplementation Reduces Plasma and Liver Cholesterol and Triglyceride Concentrations in Rats Fed a Cholesterol-free Diet publication-title: Nutr. Res. doi: 10.1016/S0271-5317(99)00118-9 – volume: 182 start-page: 59 year: 2020 ident: B32 article-title: Proteomic and Metabolomic Characterization of COVID-19 Patient Sera publication-title: Cell doi: 10.1016/j.cell.2020.05.032 – volume: 5 start-page: e140327 year: 2020 ident: B34 article-title: COVID-19 Infection Alters Kynurenine and Fatty Acid Metabolism, Correlating with IL-6 Levels and Renal Status publication-title: JCI Insight doi: 10.1172/jci.insight.140327 – year: 2021 ident: B31 article-title: Metabolic Markers Distinguish COVID-19 from Other Intensive Care Patients and Show Potential to Stratify for Disease Risk publication-title: Intensive Care Crit. Care Med. doi: 10.1101/2021.01.13.21249645 – volume: 145 start-page: 201 year: 2000 ident: B11 article-title: NMRLAB-Advanced NMR Data Processing in Matlab publication-title: J. Magn. Reson. doi: 10.1006/jmre.2000.2071 – volume: 8 start-page: 420 year: 2020 ident: B36 article-title: Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(20)30076-X – volume: 8 start-page: 92 year: 1992 ident: B21 article-title: IDL, VLDL, Chylomicrons and Atherosclerosis publication-title: Eur. J. Epidemiol. doi: 10.1007/BF00145358 – volume: 7 start-page: 423 year: 2020 ident: B3 article-title: COVID-19 and the Kidneys: An Update publication-title: Front. Med. doi: 10.3389/fmed.2020.00423 – volume: 77 start-page: 683 year: 2020 ident: B18 article-title: Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2020.1127 – volume: 5 start-page: e002765 year: 2016 ident: B13 article-title: Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.115.002765 – year: 2020 ident: B16 article-title: Caution on Kidney Dysfunctions of COVID-19 Patients publication-title: SSRN Electron. J. doi: 10.1101/2020.02.08.20021212 – volume: 12 start-page: 366 year: 2011 ident: B17 article-title: MetaboLab - Advanced NMR Data Processing and Analysis for Metabolomics publication-title: BMC Bioinf. doi: 10.1186/1471-2105-12-366 – volume: 7 start-page: 378 year: 2018 ident: B25 article-title: Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease publication-title: J. Clin. Med. doi: 10.3390/jcm7110378 – volume: 41 start-page: 2313 year: 2020 ident: B4 article-title: Low-density Lipoproteins Cause Atherosclerotic Cardiovascular Disease: Pathophysiological, Genetic, and Therapeutic Insights: A Consensus Statement from the European Atherosclerosis Society Consensus Panel publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehz962 – volume: 7 start-page: 1157 year: 2020 ident: B35 article-title: Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19 publication-title: Natl. Sci. Rev. doi: 10.1093/nsr/nwaa086 – volume: 19 start-page: 4442 year: 2020 ident: B14 article-title: Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection publication-title: J. Proteome Res.acs.jproteome. doi: 10.1021/acs.jproteome.0c00519 – volume: 72 start-page: 156 year: 2018 ident: B29 article-title: Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2018.04.050 – volume: 17 start-page: 543 year: 2020 ident: B20 article-title: COVID-19 and Cardiovascular Disease: from Basic Mechanisms to Clinical Perspectives publication-title: Nat. Rev. Cardiol. doi: 10.1038/s41569-020-0413-9 – year: 2020 ident: B2 article-title: Extrakorporale Verfahren für COVID-19-Patienten bisher wenig genutzt – volume: 40 start-page: 998 year: 2020 ident: B37 article-title: Liver Injury during Highly Pathogenic Human Coronavirus Infections publication-title: Liver Int. doi: 10.1111/liv.14435 – volume: 11 start-page: 1356 year: 2019 ident: B1 article-title: Glycine Metabolism and its Alterations in Obesity and Metabolic Diseases publication-title: Nutrients doi: 10.3390/nu11061356 |
| SSID | ssj0001503764 |
| Score | 2.3814065 |
| Snippet | Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 737039 |
| SubjectTerms | COVID-19 lipoproteins metabolomics Molecular Biosciences NMR SARS-CoV-2 |
| Title | Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34938772 https://www.proquest.com/docview/2613293059 https://pubmed.ncbi.nlm.nih.gov/PMC8686182 https://doaj.org/article/bbbf11393234463db0d98a3642a824c6 |
| Volume | 8 |
| WOSCitedRecordID | wos000731695600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2296-889X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001503764 issn: 2296-889X databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2296-889X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001503764 issn: 2296-889X databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLWgAolNxZu0UBmJFZIhjh0_ltB2BItOuwA0uyh-iZGmCZpJK5UF395rOzOaQQg2bKIoT8vnOjlHvj4XoTfGaSO4C8RU1BLYqYgJLSMtd1SoVlFqQyo2IadTNZvpi61SXzEnLNsD5457b4wJFGgKqxgoF-ZM6bRqGdDmVlXcJrNtYD1bYiqvDy5h5PA8jQkqTANM_cKAHqzoO8kgzPXOjyj59f-JZP6eK7n185k8RPsja8QfcmsfoTu-e4zu5zqSN09Qd-YHAHMxt7jtHI71qF1cbYzjShzgd_hkLIMCw3nw-Pj82-cTQjWeLPtLPO07sq4eMv_pXXrEeeSFeJPfjuMyJXyRPVhXT9HXyemX409kLKRALBf1QOpo2mK0A-lQmxL6k4sWqJbjKdFJGC4dVVJ56hSVTrMgpCmDUkHX3Ja1Z8_QXtd3_gXCsirh684tCz5w77kKzApttfY1IKJNgcp1rzZ2dBmPxS4WDaiNCESTgGgiEE0GokBvN7f8yBYbf7v4Y4Rqc2F0x04HIGaaMWaaf8VMgV6vgW5gNMUpkrbz_dWqAT3JgAAB5yzQ8wz85lWMa6ZAjBRI7oTETlt2z3Tz78mxWwklQMgd_I_GH6IHsT9SSk31Eu0Nyyv_Ct2z18N8tTxCd-VMHaXBANuzX6e34jwO6Q |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolic+and+Lipidomic+Markers+Differentiate+COVID-19+From+Non-Hospitalized+and+Other+Intensive+Care+Patients&rft.jtitle=Frontiers+in+molecular+biosciences&rft.au=Schmelter%2C+Franziska&rft.au=F%C3%B6h%2C+Bandik&rft.au=Mallagaray%2C+Alvaro&rft.au=Rahm%C3%B6ller%2C+Johann&rft.date=2021-12-02&rft.issn=2296-889X&rft.eissn=2296-889X&rft.volume=8&rft.spage=737039&rft_id=info:doi/10.3389%2Ffmolb.2021.737039&rft_id=info%3Apmid%2F34938772&rft.externalDocID=34938772 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-889X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-889X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-889X&client=summon |